Skip to main content
. 2020 Mar 11;7(10):1903730. doi: 10.1002/advs.201903730

Figure 5.

Figure 5

A) Scheme of monitoring glucose in patient CSF with plasmonic nanoreactor. B) Glucose concentrations in patient CSF determined with nanoreactor and clinical test kit. C) glucose concentrations of brain infection patient and noninfection control measured with plasmonic nanoreactor. D) Dynamic monitoring of CSF glucose of a brain infection patient during anti‐infectious therapy.